Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 863
GPP Body of Evidence Webinar Series
Good Participatory Practice Guidelines have been shaping and improving clinical research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.
Prevention Option:
STI Watch Newsletter, July 2024
In the second quarter of this year, there have been exciting new reports and updates on guidelines that could help better inform our efforts and ultimately reduce STIs.
PrEP in Black America (PIBA) and Black Public Health Academy Share Statement on Lenacapavir Results
PrEP in Black America (PIBA) and Black Public Health Academy share statement on results of twice-a-year infectable lenacapavir for PrEP proving efficacious among African cisgender women and what this means for Black communities in the US.
From The Lab To The Jab: Lessons learned and what’s next in HIV vaccine research
On 3 June 2024, AVAC hosted a webinar highlighting its Lab to Jab issue briefs on research and development, production and equitable global access to vaccines. Platforms, Not Pathogens Panelists stressed an intentional, rather than incidental...
Prevention Option:
An Overview of Lenacapavir for PrEP Trials
The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1.
Prevention Option:
Landmark Trial in South Africa and Uganda Finds Twice Yearly HIV Prevention Injection Safe and Highly Effective
Adding additional HIV prevention options means more people may find an option that is right for them. Beyond expanded choice, a twice-yearly injection has the potential to transform the way we deliver HIV prevention to people who need and want it most.
Advocates’ Guide to Doxycycline to Prevent Bacterial STIs (DoxyPEP)
DoxyPEP is a post-exposure prophylaxis used to prevent the acquisition of some bacterial STIs after sex. DoxyPEP is inexpensive, easily tolerated, and widely available. However, questions remain regarding who will benefit most from DoxyPEP and how to implement this strategy broadly to ensure equitable access.
Advocates’ Guide for PPPR
If you’re having trouble making sense of all of the initiatives around pandemic prevention, preparedness, and response (PPPR) this year, don’t worry—you’re not alone! This Advocates Guide provides a reference for the relevant information all in one place. The contents explain the major initiatives, key dates for involvement, how to get involved and make sure your priorities are heard by decision makers.
Prevention Option:
PxPulse: The Advocacy Chronicles with SMUG’s Allan Mwasa
In this episode, we’re speaking with Nsubuga Allan Mwasa, a Ugandan activist, clinical psychologist and an advocate for mental health and LGBTQ+ rights. Allan serves as Strategic Initiatives Manager at Sexual Minorities Uganda (SMUG), which has been at the forefront of the fight for LGBTQ rights.
Prevention Option:
Announcing the Next Class of Advocacy Navigators
We are thrilled to announce AVAC’s 3rd class of Advocacy Navigators! This group of 12 emerging advocates from nine countries was selected from 100s of interested applicants. They will be paired with six mentors, seasoned advocates who are alumni of AVAC’s Advocacy Fellows program. These mentors provide support and guidance as the Navigators strengthen and expand their skills in HIV prevention advocacy.
showing 1-10 of 863